metformin has been researched along with Experimental Neoplasms in 25 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The present study was designed to evaluate the effects of irinotecan hydrochloride (IRI)- or metformin hydrochloride (MET)-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles (NPs) for the treatment of glioblastoma multiforme using in vitro neuron and U-87 MG glioblastoma cell cultures and in vivo animal model." | 7.88 | Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies. ( Abd El-Aty, AM; Cetin, M; Galateanu, B; Gundogdu, B; Hacimuftuoglu, A; Jeong, JH; Jung, TW; Mezhuev, Y; Mohammadzadeh, M; Nalci, KA; Okkay, U; Stivaktakis, P; Taghizadehghalehjoughi, A; Taspinar, M; Taspinar, N; Tsatsakis, A; Ugur, AB; Uyanik, A, 2018) |
| "In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet." | 7.80 | Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014) |
| " The antidiabetic agent metformin may influence anticancer immunity in esophageal squamous cell carcinoma (ESCC)." | 5.34 | Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial. ( Bremer, E; Chen, H; Chen, S; Chen, Y; Guo, Y; Lin, P; Lin, Y; Wang, G; Wang, L; Wang, S; Xiong, X; Yeung, SJ; Zhang, H, 2020) |
| "The present study was designed to evaluate the effects of irinotecan hydrochloride (IRI)- or metformin hydrochloride (MET)-loaded poly-lactic-co-glycolic acid (PLGA) nanoparticles (NPs) for the treatment of glioblastoma multiforme using in vitro neuron and U-87 MG glioblastoma cell cultures and in vivo animal model." | 3.88 | Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies. ( Abd El-Aty, AM; Cetin, M; Galateanu, B; Gundogdu, B; Hacimuftuoglu, A; Jeong, JH; Jung, TW; Mezhuev, Y; Mohammadzadeh, M; Nalci, KA; Okkay, U; Stivaktakis, P; Taghizadehghalehjoughi, A; Taspinar, M; Taspinar, N; Tsatsakis, A; Ugur, AB; Uyanik, A, 2018) |
| "Metformin treatment is associated with a decreased risk and better prognosis of pancreatic cancer (PC) in patients with type 2 diabetes, but the mechanism of metformin's PC growth inhibition in the context of a prediabetic state is unknown." | 3.81 | Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms. ( Cifarelli, V; Devlin, KL; Dunlap, SM; Huang, J; Hursting, SD; Kaaks, R; Lashinger, LM; Pollak, MN, 2015) |
| "In the present study, the ability of metformin to inhibit skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate (TPA) was analyzed in mice maintained on either an overweight control diet or an obesity-inducing diet." | 3.80 | Metformin inhibits skin tumor promotion in overweight and obese mice. ( Angel, JM; Beltran, L; Blando, J; Checkley, LA; Cho, J; DiGiovanni, J; Hursting, SD; Rho, O, 2014) |
| " We aimed to investigate the effect of calcium electroporation in combination with metformin, a drug that affects intracellular ATP level." | 1.46 | Effect of calcium electroporation in combination with metformin in vivo and correlation between viability and intracellular ATP level after calcium electroporation in vitro. ( Frandsen, SK; Gehl, J, 2017) |
| "Metformin treated cancer cells increased macrophage expression of M1-related cytokines IL-12 and TNF-α and attenuated M2-related cytokines IL-8, IL-10, and TGF-β expression." | 1.46 | Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling. ( Chao, TT; Chiang, CF; Chien, CY; Chiu, KC; Hsu, CC; Lee, CH; Liu, SY; Shiah, SG; Shieh, YS; Su, YF, 2017) |
| "Metformin was also directly toxic to FSa cells (p = ." | 1.46 | Altered expression of a metformin-mediated radiation response in SA-NH and FSa tumor cells treated under in vitro and in vivo growth conditions. ( Grdina, DJ; Miller, RC; Murley, JS; Rademaker, AW; Senlik, RR, 2017) |
| "Metformin is an oral hypoglycaemic drug used in type 2 diabetes." | 1.42 | Anti-tumour effect of metformin in canine mammary gland tumour cells. ( Fujita, N; Matsumoto, K; Nakagawa, T; Nishimura, R; Ong, SM; Saeki, K; Saito, T; Sugano, S; Tanaka, Y; Tsuboi, M; Watanabe, M; Yoshitake, R, 2015) |
| "In the absence of hyperinsulinemia, metformin inhibited only the growth of tumors transfected with short hairpin RNA against LKB1, a finding attributable neither to an effect on host insulin level nor to activation of AMPK within the tumor." | 1.37 | Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo. ( Algire, C; Amrein, L; Bazile, M; David, S; Pollak, M; Zakikhani, M, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 17 (68.00) | 24.3611 |
| 2020's | 7 (28.00) | 2.80 |
| Authors | Studies |
|---|---|
| Popović, KJ | 1 |
| Popović, DJ | 1 |
| Miljković, D | 1 |
| Popović, JK | 1 |
| Lalošević, D | 1 |
| Poša, M | 1 |
| Čapo, I | 1 |
| Heishima, K | 1 |
| Sugito, N | 1 |
| Soga, T | 1 |
| Nishikawa, M | 1 |
| Ito, Y | 1 |
| Honda, R | 1 |
| Kuranaga, Y | 1 |
| Sakai, H | 1 |
| Ito, R | 1 |
| Nakagawa, T | 2 |
| Ueda, H | 1 |
| Akao, Y | 1 |
| Zhang, Y | 2 |
| Chen, R | 1 |
| Deng, L | 1 |
| Shuai, Z | 1 |
| Chen, M | 1 |
| Madka, V | 1 |
| Kumar, G | 1 |
| Pathuri, G | 1 |
| Lightfoot, S | 1 |
| Asch, AS | 1 |
| Mohammed, A | 1 |
| Steele, VE | 1 |
| Rao, CV | 1 |
| Wang, S | 1 |
| Lin, Y | 1 |
| Xiong, X | 1 |
| Wang, L | 1 |
| Guo, Y | 1 |
| Chen, Y | 1 |
| Chen, S | 1 |
| Wang, G | 1 |
| Lin, P | 1 |
| Chen, H | 1 |
| Yeung, SJ | 1 |
| Bremer, E | 1 |
| Zhang, H | 1 |
| Xiong, W | 1 |
| Qi, L | 1 |
| Jiang, N | 1 |
| Zhao, Q | 1 |
| Chen, L | 1 |
| Jiang, X | 1 |
| Li, Y | 1 |
| Zhou, Z | 1 |
| Shen, J | 1 |
| Yu, Y | 1 |
| Chen, J | 1 |
| Liu, S | 1 |
| Cheng, D | 1 |
| Frandsen, SK | 1 |
| Gehl, J | 1 |
| Cuyàs, E | 1 |
| Verdura, S | 1 |
| Llorach-Pares, L | 1 |
| Fernández-Arroyo, S | 1 |
| Luciano-Mateo, F | 1 |
| Cabré, N | 1 |
| Stursa, J | 1 |
| Werner, L | 1 |
| Martin-Castillo, B | 1 |
| Viollet, B | 1 |
| Neuzil, J | 1 |
| Joven, J | 1 |
| Nonell-Canals, A | 1 |
| Sanchez-Martinez, M | 1 |
| Menendez, JA | 1 |
| Lu, Z | 1 |
| Long, Y | 1 |
| Cun, X | 1 |
| Wang, X | 1 |
| Li, J | 2 |
| Mei, L | 1 |
| Yang, Y | 1 |
| Li, M | 1 |
| Zhang, Z | 1 |
| He, Q | 1 |
| Hall, DT | 1 |
| Griss, T | 1 |
| Ma, JF | 1 |
| Sanchez, BJ | 1 |
| Sadek, J | 1 |
| Tremblay, AMK | 1 |
| Mubaid, S | 1 |
| Omer, A | 1 |
| Ford, RJ | 1 |
| Bedard, N | 1 |
| Pause, A | 1 |
| Wing, SS | 1 |
| Di Marco, S | 1 |
| Steinberg, GR | 1 |
| Jones, RG | 1 |
| Gallouzi, IE | 1 |
| Taghizadehghalehjoughi, A | 1 |
| Hacimuftuoglu, A | 1 |
| Cetin, M | 1 |
| Ugur, AB | 1 |
| Galateanu, B | 1 |
| Mezhuev, Y | 1 |
| Okkay, U | 1 |
| Taspinar, N | 1 |
| Taspinar, M | 1 |
| Uyanik, A | 1 |
| Gundogdu, B | 1 |
| Mohammadzadeh, M | 1 |
| Nalci, KA | 1 |
| Stivaktakis, P | 1 |
| Tsatsakis, A | 1 |
| Jung, TW | 1 |
| Jeong, JH | 1 |
| Abd El-Aty, AM | 1 |
| Hayashi, T | 1 |
| Fujita, K | 1 |
| Matsushita, M | 1 |
| Hayashi, Y | 1 |
| Uemura, M | 1 |
| Nonomura, N | 1 |
| Checkley, LA | 1 |
| Rho, O | 1 |
| Angel, JM | 1 |
| Cho, J | 1 |
| Blando, J | 1 |
| Beltran, L | 1 |
| Hursting, SD | 2 |
| DiGiovanni, J | 1 |
| Dai, S | 1 |
| Tang, Z | 1 |
| Cao, J | 1 |
| Zhou, W | 1 |
| Li, H | 1 |
| Sampson, S | 1 |
| Dai, C | 1 |
| Cifarelli, V | 1 |
| Lashinger, LM | 1 |
| Devlin, KL | 1 |
| Dunlap, SM | 1 |
| Huang, J | 1 |
| Kaaks, R | 1 |
| Pollak, MN | 1 |
| Saeki, K | 1 |
| Watanabe, M | 1 |
| Tsuboi, M | 1 |
| Sugano, S | 1 |
| Yoshitake, R | 1 |
| Tanaka, Y | 1 |
| Ong, SM | 1 |
| Saito, T | 1 |
| Matsumoto, K | 1 |
| Fujita, N | 1 |
| Nishimura, R | 1 |
| Hong, SE | 1 |
| Jin, HO | 1 |
| Kim, HA | 1 |
| Seong, MK | 1 |
| Kim, EK | 1 |
| Ye, SK | 1 |
| Choe, TB | 1 |
| Lee, JK | 1 |
| Kim, JI | 1 |
| Park, IC | 1 |
| Noh, WC | 1 |
| Bordini, HP | 1 |
| Kremer, JL | 1 |
| Fagundes, TR | 1 |
| Melo, GP | 1 |
| Conchon-Costa, I | 1 |
| da Silva, SS | 1 |
| Cecchini, AL | 1 |
| Panis, C | 1 |
| Luiz, RC | 1 |
| Wang, PY | 1 |
| Walcott, FL | 1 |
| Kang, JG | 1 |
| Starost, MF | 1 |
| Talagala, SL | 1 |
| Zhuang, J | 1 |
| Park, JH | 1 |
| Huffstutler, RD | 1 |
| Bryla, CM | 1 |
| Mai, PL | 1 |
| Pollak, M | 2 |
| Annunziata, CM | 1 |
| Savage, SA | 1 |
| Fojo, AT | 1 |
| Hwang, PM | 1 |
| Chowdhury, S | 1 |
| Yung, E | 1 |
| Pintilie, M | 1 |
| Muaddi, H | 1 |
| Chaib, S | 1 |
| Yeung, M | 1 |
| Fusciello, M | 1 |
| Sykes, J | 1 |
| Pitcher, B | 1 |
| Hagenkort, A | 1 |
| McKee, T | 1 |
| Vellanki, R | 1 |
| Chen, E | 1 |
| Bristow, RG | 1 |
| Wouters, BG | 1 |
| Koritzinsky, M | 1 |
| Chiang, CF | 1 |
| Chao, TT | 1 |
| Su, YF | 1 |
| Hsu, CC | 1 |
| Chien, CY | 1 |
| Chiu, KC | 1 |
| Shiah, SG | 1 |
| Lee, CH | 1 |
| Liu, SY | 1 |
| Shieh, YS | 1 |
| Murley, JS | 1 |
| Miller, RC | 1 |
| Senlik, RR | 1 |
| Rademaker, AW | 1 |
| Grdina, DJ | 1 |
| Algire, C | 1 |
| Amrein, L | 1 |
| Bazile, M | 1 |
| David, S | 1 |
| Zakikhani, M | 1 |
| Bentefrit, F | 1 |
| Morgant, G | 1 |
| Viossat, B | 1 |
| Leonce, S | 1 |
| Guilbaud, N | 1 |
| Pierre, A | 1 |
| Atassi, G | 1 |
| Nguyen, HD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Pilot Study of Metformin in Patients With a Diagnosis of Li-Fraumeni Syndrome[NCT01981525] | Phase 1 | 26 participants (Actual) | Interventional | 2014-01-27 | Completed | ||
| Metabolic Regulation by Tumor Suppressor p53 in Li-Fraumeni Syndrome[NCT00406445] | 82 participants (Actual) | Observational | 2007-01-23 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for metformin and Experimental Neoplasms
| Article | Year |
|---|---|
Low-Dose Metformin Reprograms the Tumor Immune Microenvironment in Human Esophageal Cancer: Results of a Phase II Clinical Trial.
Topics: Adolescent; Adult; Aged; Animals; Apoptosis; Carcinogens; Cell Line, Tumor; Cell Proliferation; Coho | 2020 |
24 other studies available for metformin and Experimental Neoplasms
| Article | Year |
|---|---|
Disulfiram and metformin combination anticancer effect reversible partly by antioxidant nitroglycerin and completely by NF-κB activator mebendazole in hamster fibrosarcoma.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Disulfiram; Female; Fibrosarc | 2021 |
Petasin potently inhibits mitochondrial complex I-based metabolism that supports tumor growth and metastasis.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents, Phytogenic; Cell Line, Tumor; Electron Trans | 2021 |
The Effect of Metformin on the Proliferation, Apoptosis and CD133 mRNA Expression of Colon Cancer Stem Cells by Upregulation of miR 342-3p.
Topics: AC133 Antigen; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Humans; | 2021 |
Bisphosphonates Zometa and Fosamax Synergize with Metformin to Prevent AOM-Induced Colon Cancer in F344 Rat Model.
Topics: Administration, Oral; Alendronate; Animals; Anticarcinogenic Agents; Apoptosis; Azoxymethane; Cell P | 2020 |
Metformin Liposome-Mediated PD-L1 Downregulation for Amplifying the Photodynamic Immunotherapy Efficacy.
Topics: Animals; Antineoplastic Agents; Apoptosis; B7-H1 Antigen; Cell Line, Tumor; Cell Proliferation; Cell | 2021 |
ROS-responsive organosilica nanocarrier for the targeted delivery of metformin against cancer with the synergistic effect of hypoglycemia.
Topics: Animals; Antineoplastic Agents; Cell Survival; Drug Carriers; Drug Delivery Systems; Drug Screening | 2021 |
Effect of calcium electroporation in combination with metformin in vivo and correlation between viability and intracellular ATP level after calcium electroporation in vitro.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Calcium; Cell Line, Tumor; Cell Survival; El | 2017 |
Metformin directly targets the H3K27me3 demethylase KDM6A/UTX.
Topics: Animals; Biocatalysis; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Histone Demethyl | 2018 |
A size-shrinkable nanoparticle-based combined anti-tumor and anti-inflammatory strategy for enhanced cancer therapy.
Topics: Animals; Anti-Inflammatory Agents; Breast Neoplasms; Cell Line, Tumor; Doxorubicin; Female; Humans; | 2018 |
The AMPK agonist 5-aminoimidazole-4-carboxamide ribonucleotide (AICAR), but not metformin, prevents inflammation-associated cachectic muscle wasting.
Topics: Aminoimidazole Carboxamide; AMP-Activated Protein Kinase Kinases; Animals; Cachexia; Cell Line; Enzy | 2018 |
Effect of metformin/irinotecan-loaded poly-lactic-co-glycolic acid nanoparticles on glioblastoma: in vitro and in vivo studies.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Cell | 2018 |
Metformin inhibits prostate cancer growth induced by a high-fat diet in Pten-deficient model mice.
Topics: Animals; Diet, High-Fat; Disease Progression; Male; Metformin; Mice; Mice, Inbred C57BL; Mice, Trans | 2019 |
Metformin inhibits skin tumor promotion in overweight and obese mice.
Topics: Adenylate Kinase; Adiponectin; Animals; Body Weight; Carcinogenesis; Carcinoma, Squamous Cell; Diet; | 2014 |
Suppression of the HSF1-mediated proteotoxic stress response by the metabolic stress sensor AMPK.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; DNA-Binding Proteins; Enzyme Activation; H | 2015 |
Metformin and Rapamycin Reduce Pancreatic Cancer Growth in Obese Prediabetic Mice by Distinct MicroRNA-Regulated Mechanisms.
Topics: Animals; Body Weight; Cell Cycle; Diet, Diabetic; Energy Intake; Glucose Intolerance; Hypoglycemic A | 2015 |
Anti-tumour effect of metformin in canine mammary gland tumour cells.
Topics: AMP-Activated Protein Kinases; Animals; Cell Line, Tumor; Cell Survival; Dog Diseases; Dogs; Female; | 2015 |
Targeting HIF-1α is a prerequisite for cell sensitivity to dichloroacetate (DCA) and metformin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Cell Survival; Dichloroacetic Acid; Dose- | 2016 |
Protective effect of metformin in an aberrant crypt foci model induced by 1,2-dimethylhydrazine: Modulation of oxidative stress and inflammatory process.
Topics: 1,2-Dimethylhydrazine; Aberrant Crypt Foci; AMP-Activated Protein Kinases; Animals; Cell Proliferati | 2017 |
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.
Topics: Adult; Animals; Cell Proliferation; Female; Humans; Jurkat Cells; Li-Fraumeni Syndrome; Male; Metfor | 2017 |
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.
Topics: Adult; Animals; Cell Proliferation; Female; Humans; Jurkat Cells; Li-Fraumeni Syndrome; Male; Metfor | 2017 |
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.
Topics: Adult; Animals; Cell Proliferation; Female; Humans; Jurkat Cells; Li-Fraumeni Syndrome; Male; Metfor | 2017 |
Inhibiting mitochondrial respiration prevents cancer in a mouse model of Li-Fraumeni syndrome.
Topics: Adult; Animals; Cell Proliferation; Female; Humans; Jurkat Cells; Li-Fraumeni Syndrome; Male; Metfor | 2017 |
MATE2 Expression Is Associated with Cancer Cell Response to Metformin.
Topics: Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Proliferation; Cells, Cultured; Drug Resista | 2016 |
Metformin-treated cancer cells modulate macrophage polarization through AMPK-NF-κB signaling.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Blotting, Western; Cell Differentiati | 2017 |
Altered expression of a metformin-mediated radiation response in SA-NH and FSa tumor cells treated under in vitro and in vivo growth conditions.
Topics: Acetylcysteine; Animals; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Emo | 2017 |
Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo.
Topics: AMP-Activated Protein Kinases; Animals; Antineoplastic Agents; Blotting, Western; Carcinoma, Lewis L | 2011 |
Synthesis and antitumor activity of the metformin platinum (IV) complex. Crystal structure of the tetrachloro(metformin)platinum (IV) dimethylsulfoxide solvate.
Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Division; Crystallography, X-Ray; Drug Screening As | 1997 |